Pharmacyclics — Technical Presentation (June 2012)
18 slides from Pharmacyclics's technical presentation, Jun 4, 2012
Slide 1: Ibrutinib with Bendamustine/Rituximab in R/R CLL/SLL: Interim Phase Ib/II Results
Combination of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) with Bendamustine/Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of a Phase Ib/Il Study SUSAN R. O'BRI
Slide 2: Bruton's Tyrosine Kinase (BTK)
Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation B cell receptor BTK is expressed and functional across non-T-cell hematopoietic lineages BTK functions downstream in a variety of receptors + Essential element of B cell receptor signaling + Chemokine-contr
Slide 3: Ibrutinib (PCI-32765), a selective inhibitor of BTK
Ibrutinib (PCI-32765), a selective inhibitor of BTK » Formsa specific bond with cysteine-481 in BTK Highly potent BTK inhibition at 1C50=0.5 nM * Orally administered with once daily dosing resulting in 24-hr target inhibition » Nocytotoxic effect on T-cells or NK-cells » InCLL cells promotes apoptos
Slide 4: Study Design: PCYC-1108-CA
Study Design: PCYC-1108-CA * Ibrutinib in combination with bendamustine/rituximab in patients with relapsed/refractory CLL* — Ibrutinib: 420 mg/day in 28-day cycles until disease progression — Bendamustine (70 mg/m2 d1-2)/Rituximab (375mg/m? cycle 1; 500mg/m? cycles 2-6): Administered up to 6 cycles
Slide 5: Patient Eligibility
Patient Eligibility * Diagnosis of CLL or SLL and requirement for treatment per IWCLL guidelines — 21, no more than 3 prior therapies ~— Adequate end-organ function — ANC 21000x10%L = Platelets 2 50 x 10°/L — ALT<3x ULN Creatinine s 2 x ULN » No active/uncontrolled infection » ECOG 0Oor1 » No malabs
Slide 6: Patient Characteristics
Patient Characteristics Age, years Median: Range: 270 years, # (%) Diagnosis, #(%) CLL SLL ECOG Performance Status, #(%) 0 1 Prior Rx, #(%) Median: Range: 3 prior regimens: Bulky Disease, #(%) 25cm Hgb < 11 g/dL or PLT < 100K/yIL at screening 29 (97) 1(3) 15 (50) 15 (50) 2 1-3 12 (40) 16 (53) 14 (47
Slide 7: Patient Characteristics (cont.)
Patient Characteristics (cont.) Ibrutinib+ BR (N=30) Purine Analog Refractory, #(%) 11 (37) ($12 month treatment free interval following purine analog regimen) Bendamustine Refractory, # (%) 4 (13) (S 12 month treatment free interval following bendamustine containing regimen) Prognostic Markers, # (
Slide 8: Patient Disposition
Patient Disposition Follow-Up Median (months) Range Patients Still on Study, # (%) Patients Discontinued, #(%) 7 (23) Primary Reasons for Discontinuation, # (%) Proceeded to SCT 5 (17) Disease Progression 2)
Slide 9: Treatment Summary
Treatment Summary Number of Cycles of Bendamustine Received Median 6 Range 2-6 Number of Cycles of Rituximab Received Median 6 Range 2-6 Ibrutinib % Total Planned Dose Received Median o7 Range 73-100 Subjects with Dose Modifications, #(%) Bendamustine 7 (23) Rituximab ie) Ibrutinib 1(3)
Slide 10: Common Non-Hematologic AEs (All Grades)
Common Non-Hematologic AEs (All Grades) — Events Occurring in 2 20% of Patients (regardless of attribution) (N=30) Diarrhea Nausea Fatigue Rash Headache Vomiting Pyrexia Dizziness Insomnia 0% 20% 40% 60% 80% mmm Grade1 mm Grade2 mm Grade3 mm Grade4 10
Slide 11: Safety
Safety Ibrutinib+ BR N=30 Grade3 Grade 4 Grade 3/4 hematology toxicity, #(%) 5 (17) 4 (13) Neutropenia 3 (10) 4 (13) Thrombocytopenia 2(7) 0 Grade 3/4 non-hematologic toxicity in >1 pt, #(%) Rash 3(10) ie) Fatigue 2(7) 0 Tumor Lysis Syndrome 2(7) it) Cellulitis 2(7) 0 Grade 3/4 infections, #(%) 2(7)
Slide 12: Mean Percent Change From Baseline
Mean Percent Change From Baseline Ibrutinib Mediates Transient Rise in Lymphocyte Count That is Diminished in Combination with BR Blood Lymphocytes Lymph Nodes — ALC Ibrutinib single agent — sPO—Ibrutinib single agent AC Ibrutinib = BR ‘7 — 5FO—Ibrutinib = BR 20 28 a 40 re a ‘o N ‘0 oi : Cycles 8
Slide 13: Best Response
Best Response Ibrutinib+ BR (N=30) 8.1 mos median fu # (%) 2B
Slide 14: Best Response by Risk Features
Best Response by Risk Features N ORR % All Patients 30 93 270 years age € 86 Prior Rx, = 3 regimens 12 83 Hgb < 11 g/dL or PLT < 100K/pL 14 93 Del 11q present 13 100 £2 Microglobulin > 3mg/L 16 94 Purine analog refractory ng 91 Bendamustine refractory 4 75 Del 17p present 7 7A 14
Slide 15: Ibrutinib + BR Best Response
Ibrutinib + BR Best Response 100% 80% 60% 40% 20% 0% 93% } 13% 80% 3% a All Patients N=30 20/30 patients have not yet reached the full mcr response assessment MPR inclusive of bone [Nodal marrow at least 2 months after completing BR. Historical BR: ORR: 59% including 9% CRs. (Fischer 2011 JCO)..
Slide 16: Survival Probability
Survival Probability Ibrutinib + BR Progression-free Survival 1 —— ~ Censored 0.8 0.6 0.4 0.2 0.0 30 29 28 16 3 oO 0.0 25 5.0 75 10.0 12.6 Months on Study 16
Slide 17: Summary
Summary » Addition of ibrutinib to BR resulted in — 93% of patients achieved a IWCLL response with 13% CRs — Responses observed in BR/Purine-analog refractory patients — Low rate of disease progression » No added toxicity observed when adding ibrutinib toBR » Ibrutinib in combination with BR warrant
Slide 18: Acknowledgement
Acknowledgement All the patients and their families who participated in the study Investigators and clinical research staff from all the clinical centers Pharmacyclics, Inc. 8